Comparison between Infinium Pharmachem IPO and Sancode Technologies IPO.
Infinium Pharmachem IPO is a SME Fixed Price IPO proposed to list at NSE SME while Sancode Technologies IPO is a SME Fixed Price proposed to list at BSE SME.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Fixed Price | Fixed Price |
| Listing At | NSE SME | BSE SME |
| Lead Managers | Swastika Investmart Ltd. | Shreni Shares Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Bigshare Services Pvt.Ltd. |
| Market Maker | Swastika Investmart Ltd. | Shreni Shares Ltd. |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | ||
| IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Infinium Pharmachem IPO is up to ₹23.99 Cr whereas the issue size of the Sancode Technologies IPO is up to ₹4.88 Cr. The final issue price of Infinium Pharmachem IPO is ₹135.00 per share and of Sancode Technologies IPO is ₹47.00 per share.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ₹135.00 per share | ₹47.00 per share |
| Discount (Retail) | ₹0.00 per share | ₹0.00 per share |
| Discount (Employee) | ₹13.50 per share | |
| Market Lot Size | 1000 shares | 3000 shares |
| Fresh Issue Size | 17,81,000 shares | 10,38,000 shares |
| Fresh Issue Size (Amount) | up to ₹23.99 Cr | up to ₹4.88 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 17,81,000 shares | 10,38,000 shares |
| Issue Size Total (Amount) | up to ₹23.99 Cr | up to ₹4.88 Cr |
Infinium Pharmachem IPO opens on Mar 31, 2023, while Sancode Technologies IPO opens on Mar 31, 2023. The closing date of Infinium Pharmachem IPO and Sancode Technologies IPO is Apr 05, 2023, and Apr 06, 2023, respectively.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |
|---|---|---|
| Anchor Bid Date | ||
| Issue Open | Mar 31, 2023 | Mar 31, 2023 |
| Issue Close | Apr 05, 2023 | Apr 06, 2023 |
| Basis Of Allotment (Tentative) | Apr 11, 2023 | Apr 12, 2023 |
| Initiation of Refunds (Tentative) | Apr 12, 2023 | Apr 13, 2023 |
| Credit of Share (Tentative) | Apr 13, 2023 | Apr 17, 2023 |
| Listing date (Tentative) | Apr 17, 2023 | Apr 18, 2023 |
| Anchor Lockin End date 1 | ||
| Anchor Lockin End date 2 |
Infinium Pharmachem IPO P/E ratio is 7.83, as compared to Sancode Technologies IPO P/E ratio of 10.71.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 100 | 97.47 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 73.05 | 71.24 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 7.83 | 10.71 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹93.93 Cr. | ₹19.12 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 43.85 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 72 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 2.91 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹54.13 | ₹2.42 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 46.61 | 21.93 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Infinium Pharmachem IPO Retail Individual Investors (RII) are offered 8,70,000 shares while in Sancode Technologies IPO retail investors are offered 8,70,000 shares. Qualified Institutional Buyers (QIB) are offered in Infinium Pharmachem IPO and in Sancode Technologies IPO.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |
|---|---|---|
| Anchor Investor Reservation | ||
| Market Maker Reservation | 94,000 shares | 57,000 shares |
| QIB | ||
| NII | 8,70,000 shares | 5,19,000 shares |
| RII | 8,70,000 shares | 5,19,000 shares |
| Employee | 41,000 shares | |
| Others | ||
| Total | 17,81,000 shares | 10,38,000 shares |
Infinium Pharmachem IPO subscribed 1.92x in total, whereas Sancode Technologies IPO subscribed 3.68x.
| Infinium Pharmachem IPO | Sancode Technologies IPO | |
|---|---|---|
| QIB (times) | ||
| NII (times) | 1.94x | 3.98x |
| Big NII (times) | ||
| Small NII (times) | ||
| RII (times) | 2.00x | 3.39x |
| Employee (times) | 1.29x | |
| Other (times) | ||
| Total (times) | 1.92x | 3.68x |
